thalidomide and Graft vs Host Disease studies

Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.

Graft vs Host Disease: The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.

Research Excerpts

Excerpt	Relevance	Reference
"To improve the outcome of allogeneic stem cell transplantation (allo-SCT) in multiple myeloma as part of first-line treatment, we prospectively investigated the feasibility and efficacy of lenalidomide maintenance."	9.15	Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial. ( Bruijnen, CP; Cornelisse, PB; Cornelissen, JJ; Emmelot, M; Huisman, C; Huls, G; Janssen, JJ; Kersten, MJ; Kneppers, E; Lokhorst, HM; Meijer, E; Minnema, MC; Mutis, T; Sonneveld, P; van der Holt, B; Zweegman, S, 2011)
"In a randomized, placebo-controlled, double-blind trial, thalidomide or placebo together with glucocorticoids and either cyclosporine or tacrolimus was administered as initial therapy for clinical extensive chronic graft-versus-host disease (cGVHD)."	9.09	Thalidomide for treatment of patients with chronic graft-versus-host disease. ( Anasetti, C; Appelbaum, FR; Deeg, HJ; Flowers, ME; Koc, S; Leisenring, W; Martin, PJ; Nash, RA; Sanders, JE; Storb, R; Witherspoon, RP, 2000)
"Thalidomide has been reported to be an effective agent for treatment of chronic graft-versus-host disease (CGVHD)."	9.08	Thalidomide as salvage therapy for chronic graft-versus-host disease. ( Blume, KG; Chao, N; Forman, SJ; Kashyap, A; Long, GD; Margolin, K; Molina, A; Nademanee, A; Negrin, RS; Niland, JC; O'Donnell, MR; Parker, PM; Planas, I; Schmidt, GM; Smith, EP; Snyder, DS; Somlo, G; Spielberger, R; Stein, AS; Stepan, DE; Wilsman, K; Zwingenberger, K, 1995)
"This article reviews the historical development of thalidomide as an immunosuppressive agent and the current state of knowledge of thalidomide as an anti-graft-versus-host disease (GVHD) agent."	8.78	The potential use of thalidomide in the therapy of graft-versus-host disease--a review of clinical and laboratory information. ( Proctor, SJ; Wood, PM, 1990)
"We have used thalidomide in a rat major MHC mismatch model of graft-versus-host disease (GVHD)."	8.77	Thalidomide for treatment of graft-versus-host disease. ( Hess, AD; Santos, GW; Vogelsang, GB, 1988)
"Thalidomide is effective in multiple myeloma (MM), even in patients who have relapsed after high-dose therapy."	7.73	Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myélome (IFM) and the Société Française de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC). ( Attal, M; Blaise, D; Bulabois, CE; Cahn, JY; Facon, T; Garban, F; Gratecos, N; Jouet, JP; Marit, G; Mohty, M; Rio, B; Sotto, JJ; Vernant, JP; Yakoub-Agha, I, 2005)
"To improve the antimyeloma effect of donor lymphocyte infusion (DLI) after allogeneic stem cell transplantation in multiple myeloma, we investigated in a phase 1/2 study the effect of low-dose thalidomide (100 mg) followed by DLI in 18 patients with progressive disease or residual disease and prior ineffective DLI after allografting."	7.72	Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma. ( Ayuk, F; Fehse, B; Kröger, N; Lioznov, M; Nagler, A; Renges, H; Schieder, H; Shimoni, A; Zabelina, T; Zagrivnaja, M; Zander, AR, 2004)
"Thalidomide is being increasingly used after stem cell transplantation as immunosuppression for patients with chronic graft-versus-host disease, as well as for antiangiogenesis effects in patients with multiple myeloma, brain tumors, leukemia, or other malignancies."	7.71	Thalidomide in chronic graft-versus-host disease after stem cell transplantation: effects on quality of life. ( Mehta, P; Miller, S; Rodrigue, J; Sharda, S, 2002)
"Thalidomide is now widely used to treat chronic graft-versus-host disease, but its use is associated with non-teratogenic side effects such as peripheral neuropathy."	7.69	High-performance liquid chromatographic assay of plasma thalidomide: stabilization of specimens and determination of a tentative therapeutic range for chronic graft-versus-host disease. ( Boughton, BJ; Butler, M; Hale, KA; O'Brien, D; Sheehan, TM; Simpson, A; Wood, J, 1995)
"We have investigated the immunosuppressive effects of thalidomide (Thal) in a bone marrow transplant (BMT) model for graft-versus-host disease (GVHD)."	7.67	Treatment and prevention of acute graft-versus-host disease with thalidomide in a rat model. ( Gordon, G; Hess, AD; Santos, GW; Vogelsang, GB, 1986)
"Thalidomide was found to have immunosuppressive properties and it has been used in a limited number of children with cGVHD."	6.69	The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children. ( Arrigo, C; Balduzzi, A; Locasciulli, A; Miniero, R; Nesi, F; Nicolini, B; Rovelli, A; Uderzo, C; Vassallo, E, 1998)
"Thalidomide has been shown experimentally to be effective in treating GVHD."	6.67	Thalidomide for the treatment of chronic graft-versus-host disease. ( Altamonte, V; Beschorner, WE; Colvin, OM; Corio, RL; Farmer, ER; Hess, AD; Jabs, DA; Levin, LS; Vogelsang, GB; Wingard, JR, 1992)
"Thalidomide is a safe and effective drug for the treatment of chronic GVHD in children and may avoid the use of long-term corticosteroid therapy."	6.67	Thalidomide in the management of chronic graft-versus-host disease in children following bone marrow transplantation. ( Chan, KW; Cole, CH; Phillips, G; Pritchard, S; Rogers, PC, 1994)
"Thalidomide has been known to have immunosuppressive properties for over 20 years, but it has only recently been used in GVHD."	6.38	Thalidomide in the treatment of graft-versus-host disease. ( Bailey, CC; Heney, D; Lewis, IJ, 1990)
"Optimal salvage treatment for multiple myeloma relapsing after allogeneic stem cell transplantation remains to be determined."	5.39	Lenalidomide as salvage treatment for multiple myeloma relapsing after allogeneic hematopoietic stem cell transplantation: a report from the French Society of Bone Marrow and Cellular Therapy. ( Bachy, E; Bourhis, JH; Brebion, A; Coman, T; François, S; Hermine, O; Huynh, A; Lapusan, S; Lioure, B; Maury, S; Michallet, M; Milpied, N; Mohty, M; Rubio, MT; Socié, G; Uzunov, M; Vigouroux, S; Yakoub-Agha, I, 2013)
"Thalidomide was used to treat acute (n=21) or chronic (n=59) graft-vs-host disease (GVHD) in 80 haematopoietic stem cell allograft recipients after failure to respond to the combination of cyclosporine and corticosteroids with or without other agents."	5.32	Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease. ( Atra, A; Goyal, S; Horton, C; Kulkarni, S; Mehta, J; Meller, S; Ortin, M; Pinkerton, CR; Powles, R; Rudin, C; Sankpal, S; Saso, R; Singhal, S; Sirohi, B; Treleaven, J, 2003)
"Thalidomide was added to standard immunosuppressive therapy a median of 11 months (range 0-105 months) after the diagnosis of chronic GVHD."	5.31	Response to thalidomide therapy in refractory chronic graft-versus-host disease. ( Browne, PV; Davies, SM; DeFor, T; Enright, H; Filipovich, A; McGlave, PB; Miller, WJ; Ramsay, NK; Wagner, J; Weisdorf, DJ, 2000)
"Thalidomide has a role to play in the management of chronic GVHD and further studies are needed."	5.28	Thalidomide treatment for chronic graft-versus-host disease. ( Bailey, CC; Barnard, DL; Heney, D; Lewis, IJ; Norfolk, DR; Wheeldon, J, 1991)
"To improve the outcome of allogeneic stem cell transplantation (allo-SCT) in multiple myeloma as part of first-line treatment, we prospectively investigated the feasibility and efficacy of lenalidomide maintenance."	5.15	Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial. ( Bruijnen, CP; Cornelisse, PB; Cornelissen, JJ; Emmelot, M; Huisman, C; Huls, G; Janssen, JJ; Kersten, MJ; Kneppers, E; Lokhorst, HM; Meijer, E; Minnema, MC; Mutis, T; Sonneveld, P; van der Holt, B; Zweegman, S, 2011)
"In a randomized, placebo-controlled, double-blind trial, thalidomide or placebo together with glucocorticoids and either cyclosporine or tacrolimus was administered as initial therapy for clinical extensive chronic graft-versus-host disease (cGVHD)."	5.09	Thalidomide for treatment of patients with chronic graft-versus-host disease. ( Anasetti, C; Appelbaum, FR; Deeg, HJ; Flowers, ME; Koc, S; Leisenring, W; Martin, PJ; Nash, RA; Sanders, JE; Storb, R; Witherspoon, RP, 2000)
"Thalidomide has been reported to be an effective agent for treatment of chronic graft-versus-host disease (CGVHD)."	5.08	Thalidomide as salvage therapy for chronic graft-versus-host disease. ( Blume, KG; Chao, N; Forman, SJ; Kashyap, A; Long, GD; Margolin, K; Molina, A; Nademanee, A; Negrin, RS; Niland, JC; O'Donnell, MR; Parker, PM; Planas, I; Schmidt, GM; Smith, EP; Snyder, DS; Somlo, G; Spielberger, R; Stein, AS; Stepan, DE; Wilsman, K; Zwingenberger, K, 1995)
" The increasing use of post-transplant maintenance therapy with lenalidomide in patients with multiple myeloma adds to this risk after autologous HSCT."	4.93	Venous thromboembolism in hematopoietic stem cell transplant recipients. ( Chaturvedi, S; Mohty, M; Nagler, A; Neff, A; Savani, BN; Savani, U, 2016)
"This review article discusses the thalidomide therapy of diseases such as systemic sclerosis, rheumatoid arthritis, Behçet syndrome, lupus erythematosus disseminatus and graft-versus-host disease."	4.82	[Thalidomide--a new prospective therapy in rheumatology and transplantation]. ( Dziedziczko, A; Pałgan, I; Pałgan, K, 2003)
"English-language articles were identified through a MEDLINE search (1966-February 2001); key terms included thalidomide, child, graft-versus-host disease, cancer, HIV, Crohn's disease, Behçet's disease, and lupus erythematosus."	4.81	Thalidomide use in pediatric patients. ( Bessmertny, O; Pham, T, 2002)
"This article reviews the historical development of thalidomide as an immunosuppressive agent and the current state of knowledge of thalidomide as an anti-graft-versus-host disease (GVHD) agent."	4.78	The potential use of thalidomide in the therapy of graft-versus-host disease--a review of clinical and laboratory information. ( Proctor, SJ; Wood, PM, 1990)
"Thalidomide shows activity in refractory chronic graft-versus-host disease."	4.78	Thalidomide--the need for a new clinical evaluation of an old drug. ( Eger, K; Ehninger, G; Schuler, U; Stuhler, A, 1993)
"We have used thalidomide in a rat major MHC mismatch model of graft-versus-host disease (GVHD)."	4.77	Thalidomide for treatment of graft-versus-host disease. ( Hess, AD; Santos, GW; Vogelsang, GB, 1988)
"Specific inhibition of PDE4 by rolipram and apremilast had potent antifibrotic effects in bleomycin-induced skin fibrosis models, in the topoisomerase I mouse model and in murine sclerodermatous chronic graft-versus-host disease."	3.85	Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages. ( Bergmann, C; Beyer, C; Distler, JHW; Kittan, N; Maier, C; Ramming, A; Schett, G; Weinkam, R, 2017)
"Nine plasma cell myeloma patients spontaneously developed histologically proven autologous graft-versus-host disease (GVHD) limited predominantly to the gastrointestinal tract within 1 month of initial autologous hematopoietic cell transplantation (AHCT) using high-dose melphalan conditioning."	3.77	Spontaneous autologous graft-versus-host disease in plasma cell myeloma autograft recipients: flow cytometric analysis of hematopoietic progenitor cell grafts. ( Arfons, LM; Ataergin, SA; Barr, PM; Cooper, BW; Creger, RJ; Fu, P; Gerson, SL; Kaplan, D; Kaye, NM; Kindwall-Keller, TL; Laughlin, MJ; Lazarus, HM; Liu, F; Sommers, SR, 2011)
"Thalidomide is effective in multiple myeloma (MM), even in patients who have relapsed after high-dose therapy."	3.73	Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myélome (IFM) and the Société Française de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC). ( Attal, M; Blaise, D; Bulabois, CE; Cahn, JY; Facon, T; Garban, F; Gratecos, N; Jouet, JP; Marit, G; Mohty, M; Rio, B; Sotto, JJ; Vernant, JP; Yakoub-Agha, I, 2005)
"To improve the antimyeloma effect of donor lymphocyte infusion (DLI) after allogeneic stem cell transplantation in multiple myeloma, we investigated in a phase 1/2 study the effect of low-dose thalidomide (100 mg) followed by DLI in 18 patients with progressive disease or residual disease and prior ineffective DLI after allografting."	3.72	Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma. ( Ayuk, F; Fehse, B; Kröger, N; Lioznov, M; Nagler, A; Renges, H; Schieder, H; Shimoni, A; Zabelina, T; Zagrivnaja, M; Zander, AR, 2004)
"Thalidomide is being increasingly used after stem cell transplantation as immunosuppression for patients with chronic graft-versus-host disease, as well as for antiangiogenesis effects in patients with multiple myeloma, brain tumors, leukemia, or other malignancies."	3.71	Thalidomide in chronic graft-versus-host disease after stem cell transplantation: effects on quality of life. ( Mehta, P; Miller, S; Rodrigue, J; Sharda, S, 2002)
"We report two cases of severe leg ulcerations in patients being treated with thalidomide for graft-versus-host disease following bone marrow transplantation."	3.71	Severe cutaneous ulceration following treatment with thalidomide for GVHD. ( Herman, J; Klumpp, T; Mangan, K; Sabol, P; Schlossberg, H, 2001)
" Thalidomide, an antineoplastic agent, has been shown to be effective in multiple myeloma through proposed mechanisms that may include angiogenesis inhibition."	3.71	Efficacy of thalidomide therapy for extramedullary relapse of myeloma following allogeneic transplantation. ( Biagi, JJ; Grigg, AP; Mileshkin, L; Prince, HM; Westerman, DW, 2001)
"Thalidomide was administered as a therapeutic agent for chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation in a patient with breast cancer."	3.69	Thalidomide-induced perioral neuropathy. ( Elad, S; Galili, D; Garfunkel, AA; Or, R, 1997)
"Thalidomide is now widely used to treat chronic graft-versus-host disease, but its use is associated with non-teratogenic side effects such as peripheral neuropathy."	3.69	High-performance liquid chromatographic assay of plasma thalidomide: stabilization of specimens and determination of a tentative therapeutic range for chronic graft-versus-host disease. ( Boughton, BJ; Butler, M; Hale, KA; O'Brien, D; Sheehan, TM; Simpson, A; Wood, J, 1995)
"We have investigated the immunosuppressive effects of thalidomide (Thal) in a bone marrow transplant (BMT) model for graft-versus-host disease (GVHD)."	3.67	Treatment and prevention of acute graft-versus-host disease with thalidomide in a rat model. ( Gordon, G; Hess, AD; Santos, GW; Vogelsang, GB, 1986)
"In patients with chronic lymphocytic leukemia (CLL), persistence of disease after allogeneic stem cell transplantation (alloSCT) can result in poor outcomes."	2.84	Feasibility of Lenalidomide Therapy for Persistent Chronic Lymphocytic Leukemia after Allogeneic Transplantation. ( Ahmed, S; Alousi, AM; Bassett, RL; Bueso-Ramos, CE; Ciurea, SO; Gulbis, AM; Jabbour, EJ; Khouri, IF; Khouri, MR; Korbling, M; Ledesma, C; Marin, D; Patel, KK; Popat, UR; Samuels, BI; Turturro, F, 2017)
"Thalidomide was used for graft-vs-host disease, pyoderma gangrenosum, and discoid lupus with dosages ranging from 100 to 1,200 mg/day for 5 to 16 months (cumulative dosages of 24 to 384 g)."	2.70	Thalidomide-induced neuropathy. ( Chaudhry, V; Cornblath, DR; Corse, A; Freimer, M; Simmons-O'Brien, E; Vogelsang, G, 2002)
"Thalidomide was found to have immunosuppressive properties and it has been used in a limited number of children with cGVHD."	2.69	The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children. ( Arrigo, C; Balduzzi, A; Locasciulli, A; Miniero, R; Nesi, F; Nicolini, B; Rovelli, A; Uderzo, C; Vassallo, E, 1998)
"Thalidomide has been reported to be an effective agent for the treatment of chronic graft-vs."	2.68	Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host disease. ( Blume, KG; Chao, NJ; Dagis, A; Forman, SJ; Gould, KA; Hu, WW; Long, GD; Nademanee, AP; Negrin, RS; Niland, JC; Parker, PM; Snyder, DS; Tierney, DK; Wong, RM; Zwingenberger, K, 1996)
"Thalidomide has been shown experimentally to be effective in treating GVHD."	2.67	Thalidomide for the treatment of chronic graft-versus-host disease. ( Altamonte, V; Beschorner, WE; Colvin, OM; Corio, RL; Farmer, ER; Hess, AD; Jabs, DA; Levin, LS; Vogelsang, GB; Wingard, JR, 1992)
"Thalidomide is a safe and effective drug for the treatment of chronic GVHD in children and may avoid the use of long-term corticosteroid therapy."	2.67	Thalidomide in the management of chronic graft-versus-host disease in children following bone marrow transplantation. ( Chan, KW; Cole, CH; Phillips, G; Pritchard, S; Rogers, PC, 1994)
" The present review examines the drug's pharmacokinetics, discusses the main adverse renal effects that are associated with lenalidomide treatment, and makes recommendations for dosage adjustment in patients with underlying renal impairment."	2.53	[Lenalidomide nephrotoxicity]. ( Izzedine, H; Kheder El-Fekih, R, 2016)
"Thalidomide is second-line treatment for aphthous stomatitis and chronic graft-versus-host disease in children and has been prescribed for many other conditions including actinic prurigo and epidermolysis bullosa pruriginosa."	2.52	Review of thalidomide use in the pediatric population. ( Antaya, RJ; Kim, C; Yang, CS, 2015)
"New thalidomide analogues have been developed but lack clinical experience."	2.50	[Current therapeutic indications of thalidomide and lenalidomide]. ( Cosiglio, FJ; Ordi-Ros, J, 2014)
"Pomalidomide (Pomalyst(®)) is a small molecule analogue of thalidomide under development with Celgene Corporation for the oral treatment of haematological and connective tissue diseases."	2.49	Pomalidomide: first global approval. ( Elkinson, S; McCormack, PL, 2013)
"Over the last few decades therapy for multiple myeloma has improved remarkably."	2.47	Novel agents to improve outcome of allogeneic transplantation for patients with multiple myeloma. ( Einsele, H; Knop, S; Kortüm, M, 2011)
"Thalidomide was first introduced in the 1950s as a sedative but was quickly removed from the market after it was linked to cases of severe birth defects."	2.43	Thalidomide: dermatological indications, mechanisms of action and side-effects. ( Hsu, S; Huang, DB; Pang, KR; Tyring, SK; Wu, JJ, 2005)
"The activity of thalidomide in solid tumors is less prominent."	2.42	Thalidomide in cancer medicine. ( Bamias, A; Dimopoulos, MA; Eleutherakis-Papaiakovou, V, 2004)
"Thalidomide has shown great promise in advanced or refractory multiple myeloma either alone or in combination with other agents."	2.42	The promise of thalidomide: evolving indications. ( Joglekar, S; Levin, M, 2004)
"Thalidomide was originally marketed as a sedative, but was removed from the market in 1961 after it was associated with an epidemic of severe birth defects."	2.41	Thalidomide in gastrointestinal disorders. ( Bousvaros, A; Mueller, B, 2001)
"Thalidomide has various immunomodulatory effects."	2.41	[Thalidomide: new uses for an old drug]. ( Sonneveld, P; Wu, KL, 2002)
"Thalidomide has one of the most notorious drug histories because of its teratogenicity."	2.40	Thalidomide in children undergoing bone marrow transplantation: series at a single institution and review of the literature. ( Graham-Pole, J; Kedar, A; Mehta, P; Skoda-Smith, S; Wingard, JR, 1999)
"Thalidomide has been known to have immunosuppressive properties for over 20 years, but it has only recently been used in GVHD."	2.38	Thalidomide in the treatment of graft-versus-host disease. ( Bailey, CC; Heney, D; Lewis, IJ, 1990)
"Optimal salvage treatment for multiple myeloma relapsing after allogeneic stem cell transplantation remains to be determined."	1.39	Lenalidomide as salvage treatment for multiple myeloma relapsing after allogeneic hematopoietic stem cell transplantation: a report from the French Society of Bone Marrow and Cellular Therapy. ( Bachy, E; Bourhis, JH; Brebion, A; Coman, T; François, S; Hermine, O; Huynh, A; Lapusan, S; Lioure, B; Maury, S; Michallet, M; Milpied, N; Mohty, M; Rubio, MT; Socié, G; Uzunov, M; Vigouroux, S; Yakoub-Agha, I, 2013)
"Thalidomide was used to treat acute (n=21) or chronic (n=59) graft-vs-host disease (GVHD) in 80 haematopoietic stem cell allograft recipients after failure to respond to the combination of cyclosporine and corticosteroids with or without other agents."	1.32	Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease. ( Atra, A; Goyal, S; Horton, C; Kulkarni, S; Mehta, J; Meller, S; Ortin, M; Pinkerton, CR; Powles, R; Rudin, C; Sankpal, S; Saso, R; Singhal, S; Sirohi, B; Treleaven, J, 2003)
"Thalidomide was added to standard immunosuppressive therapy a median of 11 months (range 0-105 months) after the diagnosis of chronic GVHD."	1.31	Response to thalidomide therapy in refractory chronic graft-versus-host disease. ( Browne, PV; Davies, SM; DeFor, T; Enright, H; Filipovich, A; McGlave, PB; Miller, WJ; Ramsay, NK; Wagner, J; Weisdorf, DJ, 2000)
"Autoimmune haemolytic anaemia is also recognised, is frequently difficult to treat and overall prognosis is often poor, usually from associated problems."	1.31	Remission of severe, intractable autoimmune haemolytic anaemia following matched unrelated donor transplantation. ( Kinsey, SE; Pratt, G, 2001)
"Thalidomide was withdrawn from the market in the early sixties because of major teratogenic effects such as reduction defects of the limbs."	1.30	[Thalidomide once more in the spotlight]. ( Cornel, MC; de Jong-van den Berg, LT; Rutgers, J, 1998)
"Thalidomide has a role to play in the management of chronic GVHD and further studies are needed."	1.28	Thalidomide treatment for chronic graft-versus-host disease. ( Bailey, CC; Barnard, DL; Heney, D; Lewis, IJ; Norfolk, DR; Wheeldon, J, 1991)
"Thalidomide treatment was successful in the majority of animals (16 of 18)."	1.28	Therapy of chronic graft-v-host disease in a rat model. ( Friedman, KJ; Hess, AD; Santos, GW; Vogelsang, GB, 1989)

Research

Studies (107)

Authors

Clinical Trials (6)

Trial Overview

Trial Outcomes

An Additional Endpoint Analysis Would Assess the MMT-8 Score in Patients With Muscle Disease as Measured at 3 and 6 Months Compared to Baseline.

Timeframe	Studies, this research(%)	All Research%
pre-1990	17 (15.89)	18.7374
1990's	28 (26.17)	18.2507
2000's	35 (32.71)	29.6817
2010's	24 (22.43)	24.3611
2020's	3 (2.80)	2.80

Authors	Studies
Frølunde, AS	1
Wiis, MAK	1
Ben Abdallah, H	1
Elsgaard, S	1
Danielsen, AK	1
Deleuran, M	1
Vestergaard, C	1
Curtis, LM	1
Ostojic, A	1
Venzon, DJ	1
Holtzman, NG	1
Pirsl, F	1
Kuzmina, ZJ	1
Baird, K	1
Rose, JJ	1
Cowen, EW	1
Mays, JW	1
Mitchell, SA	1
Parsons-Wandell, L	1
Joe, GO	1
Comis, LE	1
Berger, A	1
Pusic, I	2
Peer, CJ	1
Figg, WD	1
Cao, L	1
Gale, RP	2
Hakim, FT	1
Pavletic, SZ	3
Lazaryan, A	1
Khouri, MR	1
Jabbour, EJ	1
Gulbis, AM	1
Turturro, F	1
Ledesma, C	1
Korbling, M	1
Samuels, BI	1
Ahmed, S	1
Alousi, AM	1
Ciurea, SO	1
Marin, D	1
Patel, KK	1
Popat, UR	1
Bueso-Ramos, CE	1
Bassett, RL	1
Khouri, IF	1
Ichiyama, S	1
Komatsu, T	1
Hoashi, T	1
Kanda, N	1
Nagai, K	1
Yamada, Y	1
Ansai, SI	1
Saeki, H	1
Elkinson, S	1
McCormack, PL	1
Ordi-Ros, J	1
Cosiglio, FJ	1
Xu, M	1
Hou, Y	1
Sheng, L	1
Peng, J	1
Kamble, RT	1
Scholoff, A	1
Obi, AG	1
Heslop, HE	1
Brenner, MK	1
Carrum, G	1
Yang, CS	1
Kim, C	1
Antaya, RJ	1
Tsukada, N	1
Shingaki, S	1
Ikeda, M	1
Miyazaki, K	1
Meshitsuka, S	1
Yoshiki, Y	1
Abe, Y	1
Suzuki, K	1
Rettig, MP	1
DiPersio, JF	1
Bauer, S	1
McFarland, K	1
Chaturvedi, S	1
Neff, A	1
Nagler, A	3
Savani, U	1
Mohty, M	3
Savani, BN	1
Kheder El-Fekih, R	1
Izzedine, H	1
Maier, C	1
Ramming, A	1
Bergmann, C	1
Weinkam, R	1
Kittan, N	1
Schett, G	1
Distler, JHW	1
Beyer, C	1
Minnema, MC	2
van der Veer, MS	1
Aarts, T	1
Emmelot, M	2
Mutis, T	2
Lokhorst, HM	3
Chen, Q	1
Lin, RB	1
Ye, YB	1
Fan, NF	1
Guo, ZQ	1
Zhou, ZF	1
Wang, XJ	1
Chen, MS	1
Chen, SP	1
Li, JY	1
Ford, CD	1
Asch, J	1
Konopa, K	1
Petersen, FB	1
Gahrton, G	2
Kortüm, M	1
Knop, S	1
Einsele, H	2
Lazarus, HM	1
Sommers, SR	1
Arfons, LM	1
Fu, P	1
Ataergin, SA	1
Kaye, NM	1
Liu, F	1
Kindwall-Keller, TL	1
Cooper, BW	1
Laughlin, MJ	1
Creger, RJ	1
Barr, PM	1
Gerson, SL	1
Kaplan, D	1
Kneppers, E	1
van der Holt, B	1
Kersten, MJ	1
Zweegman, S	1
Meijer, E	1
Huls, G	1
Cornelissen, JJ	1
Janssen, JJ	1
Huisman, C	1
Cornelisse, PB	1
Bruijnen, CP	1
Sonneveld, P	2
Patriarca, F	1
Spina, F	1
Bruno, B	1
Isola, M	1
Nozzoli, C	1
Nozza, A	1
Sperotto, A	1
Morabito, F	1
Stuhler, G	1
Festuccia, M	1
Bosi, A	1
Fanin, R	1
Corradini, P	2
El-Cheikh, J	1
Crocchiolo, R	1
Furst, S	1
Ladaique, P	1
Castagna, L	1
Faucher, C	1
Granata, A	1
Oudin, C	1
Lemarie, C	1
Calmels, B	1
Stoppa, AM	1
Schiano De Colella, JM	1
Duran, S	1
Chabannon, C	1
Blaise, D	2
St John, L	1
Gordon, SM	1
Childs, R	1
Marquesen, M	1
Wu, TX	1
Cozzarelli, T	1
Schroeder, E	1
Saria, MG	1
Fall-Dickson, JM	1
Wolschke, C	1
Stübig, T	1
Hegenbart, U	2
Schönland, S	1
Heinzelmann, M	1
Hildebrandt, Y	1
Ayuk, F	2
Atanackovic, D	1
Dreger, P	1
Zander, A	1
Kröger, N	3
Coman, T	1
Bachy, E	1
Michallet, M	1
Socié, G	1
Uzunov, M	1
Bourhis, JH	1
Lapusan, S	1
Brebion, A	1
Vigouroux, S	1
Maury, S	1
François, S	1
Huynh, A	1
Lioure, B	1
Yakoub-Agha, I	2
Hermine, O	1
Milpied, N	1
Rubio, MT	1
Wu, KL	1
Miller, S	1
Sharda, S	1
Rodrigue, J	1
Mehta, P	2
Chaudhry, V	1
Cornblath, DR	1
Corse, A	1
Freimer, M	1
Simmons-O'Brien, E	1
Vogelsang, G	1
Okafor, MC	1
Gordon, JN	1
Goggin, PM	1
Kulkarni, S	1
Powles, R	1
Sirohi, B	1
Treleaven, J	1
Saso, R	1
Horton, C	1
Atra, A	1
Ortin, M	1
Rudin, C	1
Goyal, S	1
Sankpal, S	1
Meller, S	1
Pinkerton, CR	1
Mehta, J	1
Singhal, S	1
Flowers, ME	2
Martin, PJ	2
Staumont-Sallé, D	1
Magro, L	1
Piette, F	1
Thomas, P	1
Jouet, JP	2
Catteau, B	1
Pałgan, K	1
Pałgan, I	1
Dziedziczko, A	1
Joglekar, S	1
Levin, M	1
Eleutherakis-Papaiakovou, V	1
Bamias, A	1
Dimopoulos, MA	1
Shimoni, A	1
Zagrivnaja, M	1
Lioznov, M	1
Schieder, H	1
Renges, H	1
Fehse, B	1
Zabelina, T	1
Zander, AR	1
Attal, M	1
Marit, G	1
Bulabois, CE	1
Garban, F	1
Gratecos, N	1
Rio, B	1
Vernant, JP	1
Sotto, JJ	1
Cahn, JY	1
Facon, T	1
Peñas, PF	1
Fernández-Herrera, J	1
García-Diez, A	1
Wu, JJ	1
Huang, DB	1
Pang, KR	1
Hsu, S	1
Tyring, SK	1
Nair, V	1
Sharma, A	1
Ghosh, I	1
Arora, S	1
Sahai, K	1
Dutta, V	1
van de Donk, NW	1
San Miguel, JF	1
Goldschmidt, H	1
Perez-Simon, JA	1
Zijlmans, M	1
Raymakers, RA	1
Montefusco, V	1
Ayuk, FA	1
van Oers, MH	1
Verdonck, LF	1
Chung, LW	1
Yeh, SP	1
Hsieh, CY	1
Liao, YM	1
Huang, HH	1
Lin, CY	1
Chiu, CF	1
Parker, PM	2
Chao, N	1
Nademanee, A	1
O'Donnell, MR	1
Schmidt, GM	1
Snyder, DS	2
Stein, AS	1
Smith, EP	1
Molina, A	1
Stepan, DE	1
Kashyap, A	1
Planas, I	1
Spielberger, R	1
Somlo, G	1
Margolin, K	1
Zwingenberger, K	2
Wilsman, K	1
Negrin, RS	2
Long, GD	2
Niland, JC	2
Blume, KG	2
Forman, SJ	2
Cole, CH	1
Rogers, PC	1
Pritchard, S	1
Phillips, G	1
Chan, KW	1
Boughton, BJ	2
Sheehan, TM	1
Wood, J	1
O'Brien, D	1
Butler, M	1
Simpson, A	1
Hale, KA	1
Bron, D	1
Ehninger, G	1
Eger, K	1
Stuhler, A	1
Schuler, U	1
Pizarro, A	1
Pinilla, J	1
García-Tobaruela, A	1
Lopez, J	1
Ulibarrena, C	1
Garcia-Laraña, J	1
Odriozola, J	1
Pérez de Oteyza, J	1
Sastre, JL	1
Navarro, JL	1
Altomonte, V	1
Forsyth, CJ	1
Cremer, PD	1
Torzillo, P	1
Iland, HJ	1
Young, GA	1
Chao, NJ	1
Wong, RM	1
Dagis, A	1
Nademanee, AP	1
Hu, WW	1
Gould, KA	1
Tierney, DK	1
Elad, S	1
Galili, D	1
Garfunkel, AA	1
Or, R	1
Rovelli, A	1
Arrigo, C	1
Nesi, F	1
Balduzzi, A	1
Nicolini, B	1
Locasciulli, A	1
Vassallo, E	1
Miniero, R	1
Uderzo, C	1
Sastry, PS	1
Powles, RL	1
de Jong-van den Berg, LT	1
Rutgers, J	1
Cornel, MC	1
Kedar, A	1
Graham-Pole, J	1
Skoda-Smith, S	1
Wingard, JR	2
Bez, C	1
Lodi, G	1
Sardella, A	1
Della Volpe, A	1
Carrassi, A	1
Gaziev, D	2
Galimberti, M	1
Lucarelli, G	2
Polchi, P	1
Calabrese, L	1
Fleischer, AB	1
Peuckmann, V	1
Fisch, M	1
Bruera, E	1
Browne, PV	1
Weisdorf, DJ	1
DeFor, T	2
Miller, WJ	2
Davies, SM	2
Filipovich, A	1
McGlave, PB	1
Ramsay, NK	1
Wagner, J	1
Enright, H	2
Thomas, DA	1
Kantarjian, HM	1
Koc, S	1
Leisenring, W	1
Anasetti, C	1
Deeg, HJ	1
Nash, RA	1
Sanders, JE	1
Witherspoon, RP	1
Appelbaum, FR	1
Storb, R	1
Schlossberg, H	1
Klumpp, T	1
Sabol, P	1
Herman, J	1
Mangan, K	1
Moraes, M	1
Russo, G	1
Bousvaros, A	1
Mueller, B	1
Arora, M	1
Wagner, JE	1
Blazar, BR	1
Weisdorf, DF	1
van de Poel, MH	1
Pasman, PC	1
Schouten, HC	1
Tuinmann, G	1
Hegewisch-Becker, S	1
Hossfeld, DK	1
Pratt, G	1
Kinsey, SE	1
Biagi, JJ	1
Mileshkin, L	1
Grigg, AP	1
Westerman, DW	1
Prince, HM	1
Bessmertny, O	1
Pham, T	1
Crawford, CL	1
López Gil, JA	1
Duffin, J	1
Vogelsang, GB	7
Farmer, ER	1
Hess, AD	6
Altamonte, V	1
Beschorner, WE	1
Jabs, DA	1
Corio, RL	1
Levin, LS	1
Colvin, OM	2
Heney, D	3
Norfolk, DR	1
Wheeldon, J	1
Bailey, CC	3
Lewis, IJ	3
Barnard, DL	1
Kaitin, KI	1
Wood, PM	1
Proctor, SJ	1
Randall, T	2
Codina, C	1
McCarthy, DM	2
Kanfer, EJ	1
Barrett, AJ	2
Friedman, KJ	1
Santos, GW	6
Heaton, DC	1
Lim, SH	1
McWhannell, A	1
Vora, AJ	1
Saurat, JH	1
Camenzind, M	1
Helg, C	1
Chapuis, B	1
Chen, T	1
Ringdén, O	1
Aschan, J	1
Westerberg, L	1
Kanfer, E	1
Taylor, J	1
Gordon, G	2
Wells, MC	1
Chen, TL	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Venous Thromboembolism in Hematologic Malignancy and Hematopoietic Cell Transplant Patients: a Retrospective Study of Thrombosis / Bleeding Incidence and Prophylaxis Trends[NCT05396157]		813 participants (Actual)	Observational	2021-11-01	Active, not recruiting
A Phase 2, Open Label Single Arm Study for Evaluating Safety & Efficacy of Apremilast in the Treatment of Cutaneous Disease in Patients With Recalcitrant Dermatomyositis[NCT03529955]	Phase 2	8 participants (Actual)	Interventional	2018-06-12	Completed
A Phase II Trial of GM-CSF Plus Maintenance Pembrolizumab +/- Pemetrexed After Completion of First Line Chemo-Immunotherapy in Advanced Non-Small Cell Lung Cancer Patients With PDL-1 of 1%-49%[NCT04856176]	Phase 2	83 participants (Anticipated)	Interventional	2022-01-03	Recruiting
Evaluation of Efficacy and Mechanisms of Topical Thalidomide for Chronic Graft-Versus-Host-Disease Related Stomatitis[NCT00075023]	Phase 2	10 participants (Actual)	Interventional	2003-12-31	Terminated (stopped due to unable to enroll adequate subjects)
Dose-finding Study of Lenalidomide as Maintenance Therapy in Multiple Myeloma After Allogeneic Stem Cell Transplantation[NCT00778752]	Phase 1/Phase 2	24 participants (Actual)	Interventional	2009-04-30	Completed
Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma[NCT01042704]	Phase 1	29 participants (Actual)	Interventional	2008-02-29	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

"MMT-8 (Manual Muscle Testing-8) score is a validated tool to assess muscle strength. Calculate the mean change in MMT-8 score at 3 and 6 month(s) compared to baseline in patients with muscle disease.~Units: Units on a scale. Scale goes from 0-150. 150 is perfect strength." (NCT03529955)
Timeframe: Data collected at 3 and 6 months after baseline visit

An Additional Secondary Endpoint Analysis Would Assess Quality of Life as Measured at 3 Months Compared to Quality of Life Measured at 6 Months

Intervention	score on a scale (Mean)
MMT-8 Score at 3 Months	143.3
MMT-8 Score at 6 Months	144.5

"Dermatology Life Quality Index (DLQI) is a validated tool to measure quality of life in patients with skin disease. Complete response is defined by a DLQI of zero at 3, and 6 months. Partial response is defined by a decrease of DLQI of at least 5 points at 3, and 6 months compared to baseline. Calculation is performed as the DLQI at 3, and 6 months minus the score at baseline. Missing data will be handled using the last observation carried forward approach (LOCF).~Units : Units on a scale from 0-30, higher scores represent worse outcome." (NCT03529955)
Timeframe: Data collected at 3 and 6 months after baseline visit

An Additional Secondary Endpoint Analysis Would be Durability of Response Measured Participants CDASI Activity Score or Change in Their CDASI Activity Score at 6 Months Compared to 3 Months.

Intervention	score on a scale (Mean)
DLQI Score at 3 Months	6.3
DLQI Score at 6 Months	4.2

"The durability of response will be measured using the CDASI activity score at 6 months minus CDASI activity score at 3 months. Complete response durability is defined as zero or minus difference between CDASI activity score at 6 months and CDASI activity score at 3 months. Partial response durability is defined as >4 points difference between CDASI activity score at 6 months and CDASI activity score at 3 months. Missing data will be handled using the last observation carried forward approach (LOCF).~CDASI activity score: Units on a scale from 0-100. Higher scores represent worse outcome." (NCT03529955)
Timeframe: Data collected at 6 months compared to data collected at 3 months

The Primary Endpoint Analysis Would be Overall Response Rate Measured by the Number of Participants Experiencing at Least 4 Points Decrease in CDASI Activity Score at 3 Months.

Intervention	score on a scale (Mean)
CDASI Score at 3 Months	16.9
CDASI Score at 6 Months	14

"Cutaneous dermatomyositis disease area and severity index (CDASI) activity score is a validated tool to measure skin disease activity in dermatomyositis. The overall response rate (ORR) includes partial and complete responses. Complete response is defined by a CDASI activity score of zero. Partial response is defined by a decrease of CDASI activity score of at least 4 points. Calculation is performed as the CDASI activity score at 3 month(s) minus the score at baseline. Missing data will be handled using the last observation carried forward approach (LOCF).~CDASI activity score: Units on a scale from 0-100. Higher scores represent worse outcome." (NCT03529955)
Timeframe: Data collected at 3 months after baseline visit

2. The Secondary Endpoint Analysis Would be Safety as Measured by the Number of Participants Experiencing Adverse Events and Serious Adverse Events Occurring During 6 Months of Therapy and 1 Month Follow up.

Intervention	Participants (Count of Participants)
Dermatomyositis Patients With Refractory Cutaneous Disease	7

"The proportion of participants experiencing adverse events and serious adverse events was measured over 7 months period (6 months during the study and 1 month follow up) using Common Terminology Criteria for Adverse Events (CTCAE) v5.0.~Grade refers to severity of the AE. The CTCAE displays Grades 1 to 5 with unique clinical descriptions of severity for each AE:~Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age- appropriate instrumental Activity of Daily Living (ADL) Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL Grade 4 Life-threatening consequences; urgent intervention indicated Grade 5 Death related to AE All adverse events subjects experienced were grade 1 or 2 which is mild to moderate in severity." (NCT03529955)
Timeframe: 7 months

An Additional Endpoint is to Assess the Gene Expression Profiling and Immunohistochemistry Analysis Change on Skin Biopsies at 3 Months Compared to Baseline.

Intervention	Participants (Count of Participants)
	Headache Grade 1-2	Nausea Grade 1-2	Diarrhea Grade 1-2	Herpes Zoster Grade 1-2	Influenza Grade 1-2	Pneumonia Grade 1-2	Acute sinusitis Grade 1-2	Hypertension Grade 1-2	Ocular pressure Grade 1-2
Dermatomyositis Patients With Refractory Cutaneous Disease	7	5	4	2	1	1	1	1	1

Skin biopsies from lesional skin will be performed before treatment with apremilast and after 3 months of treatment to assess changes in gene expression profiling and immunohistochemistry stain. Gene expression profiling will be analyzed using inferential statistics with a False Discovery Rate (FDR) of < 0.05. (NCT03529955)
Timeframe: Data collected at 3 months after baseline visit

An Additional Endpoint is to Assess the Immunohistochemistry Analysis Change on Skin Biopsies at 3 Months Compared to Baseline.

Intervention	Change (Number)
	Down regulated genes	Up regulated genes
Skin Biopsy at 3 Months Into Apremilast Therapy for Gene Expression Profiling	123	72
Skin Biopsy at Baseline for Gene Expression Profiling	0	0

Skin biopsies from lesional skin will be performed before treatment with apremilast and after 3 months of treatment to assess changes in immunohistochemistry stain. (NCT03529955)
Timeframe: Data collected at 3 months after baseline visit

Mean Percentage Change in Total Surface Area of Oral Ulceration.

Intervention	Percentage of positive cell detection (Mean)
	STAT1	STAT3
Skin Biopsy at 3 Months Into Apremilast Therapy for IHC	50.1	17.4
Skin Biopsy at Baseline for IHC	96.2	44.3

Mean percentage change in total surface area of oral ulceration (NCT00075023)
Timeframe: baseline to 4 weeks

Intervention	percentage change (Mean)
Thalidomide Gel	-66
Placebo	-59

Article	Year
Non-Atopic Chronic Nodular Prurigo (Prurigo Nodularis Hyde): A Systematic Review of Best-Evidenced Treatment Options. Dermatology (Basel, Switzerland), 2022, Volume: 238, Issue:5 Topics: Chronic Disease; Graft vs Host Disease; Humans; Hypersensitivity, Immediate; Prurigo; Pruritus; Skin	2022
Pomalidomide: first global approval. Drugs, 2013, Volume: 73, Issue:6 Topics: Angiogenesis Inhibitors; Animals; Clinical Trials as Topic; Drug Approval; Graft vs Host Disease; Hu	2013
[Current therapeutic indications of thalidomide and lenalidomide]. Medicina clinica, 2014, Apr-22, Volume: 142, Issue:8 Topics: Abnormalities, Drug-Induced; Anti-Inflammatory Agents; Antineoplastic Agents; Collagen Diseases; End	2014
Therapeutic effects of thalidomide in hematologic disorders: a review. Frontiers of medicine, 2013, Volume: 7, Issue:3 Topics: Angiogenesis Inhibitors; Clinical Trials as Topic; Graft vs Host Disease; Hematologic Neoplasms; Hum	2013
Review of thalidomide use in the pediatric population. Journal of the American Academy of Dermatology, 2015, Volume: 72, Issue:4 Topics: Abnormalities, Drug-Induced; Adolescent; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Au	2015
Venous thromboembolism in hematopoietic stem cell transplant recipients. Bone marrow transplantation, 2016, Volume: 51, Issue:4 Topics: Allografts; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Mu	2016
[Lenalidomide nephrotoxicity]. Bulletin du cancer, 2016, Volume: 103, Issue:5 Topics: Graft vs Host Disease; Humans; Immunologic Factors; Kidney; Kidney Tubules; Lenalidomide; Necrosis;	2016
Progress in allogeneic transplantation for multiple myeloma. European journal of haematology, 2010, Volume: 85, Issue:4 Topics: Antineoplastic Agents; Cyclophosphamide; Disease-Free Survival; Graft vs Host Disease; Hematopoietic	2010
Novel agents to improve outcome of allogeneic transplantation for patients with multiple myeloma. Future oncology (London, England), 2011, Volume: 7, Issue:1 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Graft vs Host Di	2011
[Thalidomide: new uses for an old drug]. Nederlands tijdschrift voor geneeskunde, 2002, Aug-03, Volume: 146, Issue:31 Topics: Angiogenesis Inhibitors; Drug Approval; Erythema Nodosum; Graft vs Host Disease; Humans; Immune Syst	2002
Thalidomide for erythema nodosum leprosum and other applications. Pharmacotherapy, 2003, Volume: 23, Issue:4 Topics: Animals; Cachexia; Erythema Nodosum; Graft vs Host Disease; Humans; Leprosy, Lepromatous; Multiple M	2003
Thalidomide and its derivatives: emerging from the wilderness. Postgraduate medical journal, 2003, Volume: 79, Issue:929 Topics: Adjuvants, Immunologic; Cachexia; Crohn Disease; Graft vs Host Disease; Hematologic Neoplasms; Human	2003
Evaluation of thalidomide for treatment or prevention of chronic graft-versus-host disease. Leukemia & lymphoma, 2003, Volume: 44, Issue:7 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Clinical Trials as Topic; Graft vs Host Dis	2003
[Thalidomide--a new prospective therapy in rheumatology and transplantation]. Wiadomosci lekarskie (Warsaw, Poland : 1960), 2003, Volume: 56, Issue:11-12 Topics: Arthritis, Rheumatoid; Behcet Syndrome; Graft vs Host Disease; Humans; Immunosuppressive Agents; Int	2003
The promise of thalidomide: evolving indications. Drugs of today (Barcelona, Spain : 1998), 2004, Volume: 40, Issue:3 Topics: Cachexia; Carcinoma, Renal Cell; Clinical Trials as Topic; Erythema Nodosum; Graft vs Host Disease;	2004
Thalidomide in cancer medicine. Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:8 Topics: Angiogenesis Inhibitors; Cachexia; Clinical Trials as Topic; Graft vs Host Disease; Humans; Multiple	2004
Dermatologic treatment of cutaneous graft versus host disease. American journal of clinical dermatology, 2004, Volume: 5, Issue:6 Topics: Clinical Trials as Topic; Etretinate; Graft vs Host Disease; Humans; Immunosuppressive Agents; PUVA	2004
Thalidomide: dermatological indications, mechanisms of action and side-effects. The British journal of dermatology, 2005, Volume: 153, Issue:2 Topics: Adult; Behcet Syndrome; Dermatologic Agents; Erythema; Graft vs Host Disease; Histiocytosis, Langerh	2005
Graft-versus-host disease. Current opinion in oncology, 1994, Volume: 6, Issue:4 Topics: Acute Disease; Adolescent; Adult; Bone Marrow Transplantation; Child; Chronic Disease; Clinical Tria	1994
Thalidomide--the need for a new clinical evaluation of an old drug. Bone marrow transplantation, 1993, Volume: 12 Suppl 3 Topics: Graft vs Host Disease; Humans; Thalidomide	1993
Thalidomide in children undergoing bone marrow transplantation: series at a single institution and review of the literature. Pediatrics, 1999, Volume: 103, Issue:4 Topics: Acute Disease; Adolescent; Bone Marrow Transplantation; Child; Child, Preschool; Chronic Disease; Gr	1999
Chronic graft-versus-host disease: is there an alternative to the conventional treatment? Bone marrow transplantation, 2000, Volume: 25, Issue:7 Topics: Chronic Disease; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Photochemot	2000
Thalidomide: current and potential clinical applications. The American journal of medicine, 2000, Apr-15, Volume: 108, Issue:6 Topics: Angiogenesis Inhibitors; Anti-HIV Agents; Arthritis, Rheumatoid; Behcet Syndrome; Dermatologic Agent	2000
Potential novel uses of thalidomide: focus on palliative care. Drugs, 2000, Volume: 60, Issue:2 Topics: Angiogenesis Inhibitors; Animals; Cachexia; Cytokines; Erythema Nodosum; Graft vs Host Disease; Huma	2000
Current role of thalidomide in cancer treatment. Current opinion in oncology, 2000, Volume: 12, Issue:6 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Clinical Trials as Topic; Graft vs Host Disease; Hum	2000
Novel approaches to the treatment of chronic graft-versus-host disease. Expert opinion on investigational drugs, 2001, Volume: 10, Issue:5 Topics: Chronic Disease; Graft vs Host Disease; Humans; Lymphoid Tissue; Mycophenolic Acid; Photochemotherap	2001
Thalidomide and its dermatologic uses. The American journal of the medical sciences, 2001, Volume: 321, Issue:5 Topics: Acquired Immunodeficiency Syndrome; Behcet Syndrome; Dermatologic Agents; Erythema Nodosum; Facial D	2001
Thalidomide in gastrointestinal disorders. Drugs, 2001, Volume: 61, Issue:6 Topics: Behcet Syndrome; Cell Adhesion; Colitis, Ulcerative; Crohn Disease; Gastrointestinal Diseases; Graft	2001
[New indications for thalidomide?]. Deutsche medizinische Wochenschrift (1946), 2001, Oct-19, Volume: 126, Issue:42 Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Angiogenesis Inhibitors; Animals; Anti-HIV Agents; A	2001
Thalidomide use in pediatric patients. The Annals of pharmacotherapy, 2002, Volume: 36, Issue:3 Topics: Adolescent; Child; Chronic Disease; Female; Graft vs Host Disease; Humans; Hypnotics and Sedatives;	2002
[Thalidomide and graft verses host disease: basis for a new indication and side effects]. Medicina clinica, 1992, Oct-31, Volume: 99, Issue:14 Topics: Animals; Graft vs Host Disease; Humans; Thalidomide	1992
The potential use of thalidomide in the therapy of graft-versus-host disease--a review of clinical and laboratory information. Leukemia research, 1990, Volume: 14, Issue:5 Topics: Acute Disease; Animals; Chronic Disease; Down-Regulation; Graft vs Host Disease; Humans; Immunosuppr	1990
Thalidomide in the treatment of graft-versus-host disease. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 1990, Volume: 44, Issue:4 Topics: Bone Marrow Transplantation; Child, Preschool; Graft vs Host Disease; Humans; Male; Postoperative Co	1990
Thalidomide for the therapy of graft-versus-host disease following allogeneic bone marrow transplantation. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 1989, Volume: 43, Issue:9 Topics: Adolescent; Adult; Bone Marrow Transplantation; Child; Female; Graft vs Host Disease; Humans; Male;	1989
Thalidomide for treatment of graft-versus-host disease. Bone marrow transplantation, 1988, Volume: 3, Issue:5 Topics: Animals; Bone Marrow Transplantation; Drug Evaluation; Drug Evaluation, Preclinical; Graft vs Host D	1988

Article	Year
A randomized phase 2 trial of pomalidomide in subjects failing prior therapy for chronic graft-versus-host disease. Blood, 2021, 02-18, Volume: 137, Issue:7 Topics: Adolescent; Adult; Aged; Allografts; Disease Susceptibility; Dose-Response Relationship, Drug; Drug	2021
Feasibility of Lenalidomide Therapy for Persistent Chronic Lymphocytic Leukemia after Allogeneic Transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2017, Volume: 23, Issue:8 Topics: Acute Disease; Aged; Allografts; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Dis	2017
Phase-1/-2 study of pomalidomide in chronic GvHD. Bone marrow transplantation, 2016, Volume: 51, Issue:4 Topics: Adult; Chronic Disease; Female; Graft vs Host Disease; Humans; Male; Middle Aged; Pilot Projects; Th	2016
Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+Foxp3+ T cells. Leukemia, 2009, Volume: 23, Issue:3 Topics: Adjuvants, Immunologic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone;	2009
Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial. Blood, 2011, Sep-01, Volume: 118, Issue:9 Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Cyclophosphamide; Cycl	2011
Lenalidomide plus donor-lymphocytes infusion after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with high-risk multiple myeloma. Experimental hematology, 2012, Volume: 40, Issue:7 Topics: Aged; Antineoplastic Agents; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Immunothe	2012
Topical thalidomide gel in oral chronic GVHD and role of in situ cytokine expression in monitoring biological activity. Bone marrow transplantation, 2013, Volume: 48, Issue:4 Topics: Administration, Topical; Adult; Chronic Disease; Cytokines; Double-Blind Method; Female; Gels; Gene	2013
Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I/II dose-finding study. Experimental hematology, 2013, Volume: 41, Issue:2 Topics: Adult; Aged; Combined Modality Therapy; Disease Progression; Dose-Response Relationship, Immunologic	2013
Thalidomide-induced neuropathy. Neurology, 2002, Dec-24, Volume: 59, Issue:12 Topics: Adult; Bone Marrow Transplantation; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents;	2002
Thalidomide as salvage therapy for chronic graft-versus-host disease. Blood, 1995, Nov-01, Volume: 86, Issue:9 Topics: Adolescent; Adult; Bone Marrow Transplantation; Child; Chronic Disease; Constipation; Cyclosporine;	1995
Thalidomide in the management of chronic graft-versus-host disease in children following bone marrow transplantation. Bone marrow transplantation, 1994, Volume: 14, Issue:6 Topics: Adolescent; Bone Marrow Transplantation; Child; Child, Preschool; Chronic Disease; Female; Graft vs	1994
Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host disease. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 1996, Volume: 2, Issue:2 Topics: Adolescent; Adult; Bone Marrow Transplantation; Double-Blind Method; Female; Graft vs Host Disease;	1996
The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children. Bone marrow transplantation, 1998, Volume: 21, Issue:6 Topics: Adolescent; Adult; Anemia; Bone Marrow Transplantation; Child; Child, Preschool; Female; Graft vs Ho	1998
Thalidomide for treatment of patients with chronic graft-versus-host disease. Blood, 2000, Dec-01, Volume: 96, Issue:12 Topics: Actuarial Analysis; Chronic Disease; Cyclosporine; Double-Blind Method; Drug Therapy, Combination; G	2000
Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2001, Volume: 7, Issue:5 Topics: Bone Marrow Transplantation; Chronic Disease; Cyclosporine; Drug Therapy, Combination; Graft vs Host	2001
Thalidomide for the treatment of chronic graft-versus-host disease. The New England journal of medicine, 1992, Apr-16, Volume: 326, Issue:16 Topics: Adolescent; Adult; Bone Marrow Transplantation; Child; Chronic Disease; Graft vs Host Disease; Human	1992

Article	Year
New is forgotten old: IMiDs against chronic GVHD. Blood, 2021, 02-18, Volume: 137, Issue:7 Topics: Graft vs Host Disease; Humans; Immunologic Factors; Thalidomide	2021
Treatment with apremilast was beneficial for chronic graft-versus-host disease skin lesion in a patient with psoriasis. The Journal of dermatology, 2019, Volume: 46, Issue:6 Topics: Administration, Oral; Biopsy; Bone Marrow Transplantation; Chronic Disease; Cytarabine; Graft vs Hos	2019
Neuropathic dermatomes and cutaneous ulceration in patients with chronic GVHD. Bone marrow transplantation, 2014, Volume: 49, Issue:7 Topics: Bone Marrow Transplantation; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Leukem	2014
[Graft-versus-host disease associated with lenalidomide maintenance after allogeneic transplantation for relapsed/refractory multiple myeloma]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2015, Volume: 56, Issue:7 Topics: Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalid	2015
Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages. Annals of the rheumatic diseases, 2017, Volume: 76, Issue:6 Topics: Animals; Bleomycin; Cell Differentiation; Collagen; Cyclic Nucleotide Phosphodiesterases, Type 4; Cy	2017
The combined administration of partially HLA-matched irradiated allogeneic lymphocytes and thalidomide in advanced renal-cell carcinoma: a case report. Medical oncology (Northwood, London, England), 2010, Volume: 27, Issue:2 Topics: Carcinoma, Renal Cell; Combined Modality Therapy; Graft vs Host Disease; Histocompatibility Testing;	2010
CR with lenalidomide in del(5)(q13q33) AML relapsing after allogeneic hematopoietic SCT. Bone marrow transplantation, 2010, Volume: 45, Issue:2 Topics: Aged; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Graft vs Host	2010
Spontaneous autologous graft-versus-host disease in plasma cell myeloma autograft recipients: flow cytometric analysis of hematopoietic progenitor cell grafts. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011, Volume: 17, Issue:7 Topics: Acute Disease; Adrenal Cortex Hormones; Adult; Aged; Biomarkers; Boronic Acids; Bortezomib; Case-Con	2011
Allogeneic transplantation in multiple myeloma. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2011, Volume: 183 Topics: Animals; Boronic Acids; Bortezomib; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation;	2011
Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: a multicenter retrospective study based on donor availability. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012, Volume: 18, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease-Free Survival; Graft vs Host	2012
Lenalidomide as salvage treatment for multiple myeloma relapsing after allogeneic hematopoietic stem cell transplantation: a report from the French Society of Bone Marrow and Cellular Therapy. Haematologica, 2013, Volume: 98, Issue:5 Topics: Adult; Antineoplastic Agents; Female; France; Graft vs Host Disease; Hematopoietic Stem Cell Transpl	2013
Thalidomide in chronic graft-versus-host disease after stem cell transplantation: effects on quality of life. International journal of hematology, 2002, Volume: 76, Issue:4 Topics: Case-Control Studies; Chronic Disease; Graft vs Host Disease; Humans; Immunosuppressive Agents; Neop	2002
Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease. Bone marrow transplantation, 2003, Volume: 32, Issue:2 Topics: Acute Disease; Adolescent; Adrenal Cortex Hormones; Adult; Child; Child, Preschool; Chronic Disease;	2003
Chronic graft-versus-host disease revealed by lichenoid vulvar lesions successfully treated with thalidomide. Acta dermato-venereologica, 2003, Volume: 83, Issue:4 Topics: Administration, Oral; Adult; Bone Marrow Transplantation; Diagnosis, Differential; Female; Graft vs	2003
Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma. Blood, 2004, Nov-15, Volume: 104, Issue:10 Topics: Adult; Combined Modality Therapy; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hu	2004
Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myélome (IFM) and the Société Française de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC). Bone marrow transplantation, 2005, Volume: 35, Issue:2 Topics: Adult; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle	2005
Extensive chronic graft-versus-host disease of skin successfully treated with thalidomide. The Journal of the Association of Physicians of India, 2005, Volume: 53 Topics: Adult; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Leukemia, Myelogenous, Chron	2005
Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma. Blood, 2006, Apr-15, Volume: 107, Issue:8 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Graft vs Host Disease; Humans; Immunosuppr	2006
Life-threatening acute pancreatitis due to thalidomide therapy for chronic graft-versus-host disease. Annals of hematology, 2008, Volume: 87, Issue:5 Topics: Adolescent; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosu	2008
High-performance liquid chromatographic assay of plasma thalidomide: stabilization of specimens and determination of a tentative therapeutic range for chronic graft-versus-host disease. Annals of clinical biochemistry, 1995, Volume: 32 ( Pt 1) Topics: Chromatography, High Pressure Liquid; Chronic Disease; Dose-Response Relationship, Drug; Drug Stabil	1995
[Treatment with thalidomide and production of tumor necrosis factor alpha]. Medicina clinica, 1993, Jun-19, Volume: 101, Issue:4 Topics: Graft vs Host Disease; HIV Infections; Humans; Thalidomide; Tumor Necrosis Factor-alpha	1993
Thalidomide as therapy for intestinal chronic GVHD. Bone marrow transplantation, 1993, Volume: 11, Issue:3 Topics: Adult; Bone Marrow Transplantation; Graft vs Host Disease; Humans; Intestinal Diseases; Male; Precur	1993
Use of thalidomide for CGVHD defended. Oncology nursing forum, 1993, Volume: 20, Issue:3 Topics: Bone Marrow Transplantation; Clinical Trials as Topic; Graft vs Host Disease; Humans; Survival Rate;	1993
Thalidomide responsive chronic pulmonary GVHD. Bone marrow transplantation, 1996, Volume: 17, Issue:2 Topics: Adrenal Cortex Hormones; Adult; Bone Marrow Transplantation; Bronchiolitis Obliterans; Cyclosporine;	1996
Thalidomide-induced perioral neuropathy. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 1997, Volume: 84, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adju	1997
A cautious comeback for thalidomide. Harvard health letter, 1998, Volume: 23, Issue:4 Topics: Abnormalities, Drug-Induced; Antineoplastic Agents; Graft vs Host Disease; HIV Wasting Syndrome; Hum	1998
Thalidomide for chronic GVHD. Bone marrow transplantation, 1998, Volume: 22, Issue:9 Topics: Chronic Disease; Graft vs Host Disease; Humans; Immunosuppressive Agents; Thalidomide	1998
[Thalidomide once more in the spotlight]. Nederlands tijdschrift voor geneeskunde, 1998, Nov-14, Volume: 142, Issue:46 Topics: Adult; Bone Marrow Transplantation; Contraindications; Drug and Narcotic Control; Drug Approval; Fem	1998
Oral lichenoid lesions after thalidomide treatment. Dermatology (Basel, Switzerland), 1999, Volume: 199, Issue:2 Topics: Adult; Diagnosis, Differential; Female; Graft vs Host Disease; Humans; Lichen Planus, Oral; Thalidom	1999
Thalidomide: new preparation. For well-defined indications. Prescrire international, 1998, Volume: 7, Issue:37 Topics: Behcet Syndrome; Clinical Trials as Topic; Erythema Nodosum; France; Graft vs Host Disease; Humans;	1998
Response to thalidomide therapy in refractory chronic graft-versus-host disease. Bone marrow transplantation, 2000, Volume: 26, Issue:8 Topics: Chronic Disease; Female; Graft vs Host Disease; Humans; Male; Thalidomide	2000
Severe cutaneous ulceration following treatment with thalidomide for GVHD. Bone marrow transplantation, 2001, Volume: 27, Issue:2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modalit	2001
The use of thalidomide in chronic refractory graft versus host disease. The Netherlands journal of medicine, 2001, Volume: 59, Issue:2 Topics: Adult; Bone Marrow Transplantation; Chronic Disease; Female; Graft vs Host Disease; Humans; Immunosu	2001
Remission of severe, intractable autoimmune haemolytic anaemia following matched unrelated donor transplantation. Bone marrow transplantation, 2001, Volume: 28, Issue:8 Topics: Adrenal Cortex Hormones; Alemtuzumab; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal; Antibod	2001
Efficacy of thalidomide therapy for extramedullary relapse of myeloma following allogeneic transplantation. Bone marrow transplantation, 2001, Volume: 28, Issue:12 Topics: Adult; Antineoplastic Agents; Bone Marrow Transplantation; Female; Graft vs Host Disease; Humans; In	2001
Thalidomide neuropathy. The New England journal of medicine, 1992, Sep-03, Volume: 327, Issue:10 Topics: Graft vs Host Disease; Humans; Peripheral Nervous System Diseases; Thalidomide	1992
Phases in a drug's use. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 1992, Sep-01, Volume: 147, Issue:5 Topics: Bone Marrow Transplantation; Canada; Drug Utilization; Graft vs Host Disease; Humans; Thalidomide	1992
Thalidomide treatment for chronic graft-versus-host disease. British journal of haematology, 1991, Volume: 78, Issue:1 Topics: Adolescent; Adult; Child; Chronic Disease; Female; Graft vs Host Disease; Humans; Male; Middle Aged;	1991
Graft-versus-host disease. The New England journal of medicine, 1991, Aug-01, Volume: 325, Issue:5 Topics: Graft vs Host Disease; Humans; Thalidomide	1991
Thalidomide's back in the news, but in more favorable circumstances. JAMA, 1990, Mar-16, Volume: 263, Issue:11 Topics: Animals; Graft vs Host Disease; Humans; Immunosuppression Therapy; Thalidomide	1990
Investigational new drug (US) 'orphan' trials now use thalidomide from two sources. JAMA, 1990, Mar-16, Volume: 263, Issue:11 Topics: Drug Industry; Erythema Nodosum; Graft vs Host Disease; Leprosy, Lepromatous; Orphan Drug Production	1990
[Thalidomide 1989]. Medicina clinica, 1989, Apr-22, Volume: 92, Issue:15 Topics: Animals; Bone Marrow Transplantation; Cyclosporins; Drug Therapy, Combination; Graft vs Host Disease	1989
Therapy of chronic graft-v-host disease in a rat model. Blood, 1989, Volume: 74, Issue:1 Topics: Animals; Azathioprine; Cyclosporins; Disease Models, Animal; Drug Synergism; Graft vs Host Disease;	1989
Failure of thalidomide to control bronchiolitis obliterans post bone marrow transplant. Bone marrow transplantation, 1989, Volume: 4, Issue:5 Topics: Adult; Bone Marrow Transplantation; Bronchiolitis Obliterans; Graft vs Host Disease; Humans; Leukemi	1989
Successful treatment with thalidomide of acute graft-versus-host disease after bone-marrow transplantation. Lancet (London, England), 1988, Jan-16, Volume: 1, Issue:8577 Topics: Adult; Bone Marrow Transplantation; Graft vs Host Disease; Humans; Leukemia, Lymphoid; Male; Thalido	1988
Thalidomide for graft-versus-host disease after bone marrow transplantation. Lancet (London, England), 1988, Feb-13, Volume: 1, Issue:8581 Topics: Acute Disease; Adult; Bone Marrow Transplantation; Drug Administration Schedule; Graft vs Host Disea	1988
Thalidomide for graft-versus-host disease. Lancet (London, England), 1988, Apr-09, Volume: 1, Issue:8589 Topics: Chronic Disease; Dose-Response Relationship, Drug; Graft vs Host Disease; Humans; Thalidomide	1988
Thalidomide for severe acute graft-versus-host disease. Lancet (London, England), 1988, Sep-03, Volume: 2, Issue:8610 Topics: Acute Disease; Adolescent; Adult; Bone Marrow Transplantation; Drug Administration Schedule; Graft v	1988
Thalidomide for graft-versus-host disease. Lancet (London, England), 1988, Nov-12, Volume: 2, Issue:8620 Topics: Acute Disease; Adolescent; Adult; Bone Marrow Transplantation; Child; Chronic Disease; Female; Graft	1988
Thalidomide for chronic graft-versus-host disease in children. Lancet (London, England), 1988, Dec-03, Volume: 2, Issue:8623 Topics: Adolescent; Child, Preschool; Chronic Disease; Graft vs Host Disease; Humans; Male; Thalidomide	1988
Treatment and prevention of acute graft-versus-host disease with thalidomide in a rat model. Transplantation, 1986, Volume: 41, Issue:5 Topics: Animals; Bone Marrow Transplantation; Female; Graft Survival; Graft vs Host Disease; Immunosuppressi	1986
Thalidomide back in good graces--seems to help GVHD patients. Oncology (Williston Park, N.Y.), 1988, Volume: 2, Issue:9 Topics: Acute Disease; Adolescent; Adult; Bone Marrow Transplantation; Child; Child, Preschool; Chronic Dise	1988
Combination low-dose thalidomide and cyclosporine prophylaxis for acute graft-versus-host disease in a rat mismatched model. Transplantation proceedings, 1988, Volume: 20, Issue:2 Suppl 2 Topics: Animals; Bone Marrow Transplantation; Cyclosporins; Drug Therapy, Combination; Graft vs Host Disease	1988
Quest to improve marrow transplant success yields new approaches to graft-vs-host disease. JAMA, 1987, Sep-18, Volume: 258, Issue:11 Topics: Bone Marrow Transplantation; Graft vs Host Disease; Humans; Leukemia; Thalidomide	1987
Thalidomide induction of bone marrow transplantation tolerance. Transplantation proceedings, 1987, Volume: 19, Issue:1 Pt 3 Topics: Aminoglutethimide; Animals; Bone Marrow Transplantation; Female; Fluorescence; Graft vs Host Disease	1987
New methods of treatment for renal allotransplants using the baboon as a primate experimental model. The Journal of urology, 1969, Volume: 102, Issue:5 Topics: Animals; Antibodies; Azathioprine; Cyclophosphamide; Female; Globulins; Graft vs Host Disease; Haplo	1969

thalidomide and Graft vs Host Disease